1 completed, 1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow DNA, Recombinant: new trials by email Literature Review of DNA, Recombinant trials Research Report on DNA, Recombinant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program. Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine - COVID-19, Long Haul | Phase 4 | Recruiting | Well- Konnect Healthcare Services and Research Firm | 100 | 2024-03-01 | 2024-11-27 |
| Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants Multicomponent Meningococcal B Vaccine, Meningococcal Group B Vaccine MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed) - Meningococcal Immunisation, Healthy Volunteers | Phase 1 | Terminated | Sanofi Pasteur, a Sanofi Company | 576 | 2021-03-29 | 2025-10-10 |
| Observational Study of Somatropin Treatment in Children Somatropin (recombinant deoxyribonucleic acid [rDNA] origin) - Growth Hormone (GH) Deficiency, Short Stature Homeobox Containing Gene (SHOX) Deficiency | Completed | Eli Lilly and Company | 22845 | 1999-04-01 | 2019-05-13 |
Post-Acute COVID-19 Syndrome (1)
Eli Lilly and Company (1) · Sanofi Pasteur, a Sanofi Company (1) · Well- Konnect Healthcare Services and Research Firm (1)
United States (2) · Puerto Rico (1)
PMID 21490076, PMID 23689058, PMID 24088548, PMID 28575299, PMID 30201821, PMID 30219920
2023 (1)